NASDAQ: GRIGri Bio Inc Stock
$1.35-0.71 (-34.47%)
Updated Dec 8, 2025
GRI Price
$1.35
Fair Value Price
N/A
Market Cap
$4.41M
52 Week Low
$1.10
52 Week High
$16.92
P/E
0.09x
P/B
2.21x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.4
Operating Cash Flow
-$9M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GRI Overview
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GRI's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GRI
Ranked#468 of 488
Ranked#468 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $326.49 | A | |
| $6.68 | A | |
| $21.00 | A |
Be the first to know about important GRI news, forecast changes, insider trades & much more!
GRI News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRI is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GRI is good value based on its earnings relative to its share price (0.09x), compared to the US market average (45.87x)
P/E vs Market Valuation
GRI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more GRI due diligence checks available for Premium users.
Valuation
GRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.09x
Industry
172.86x
Market
45.87x
GRI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GRI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
GRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.21x
Industry
5.27x
GRI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRI's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.4M
Profit Margin
0%
GRI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.8M
Liabilities
$2.8M
Debt to equity
1.4
GRI's short-term assets ($4.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRI's short-term assets ($4.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$1.2M
GRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRI vs Biotech Stocks
Gri Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.